Expiration date: 10/2025
Composition
1 tablet contains Active ingredient: 20 mg of trimetazidine dihydrochloride.
Pharmacotherapeutic group: Antihypoxanth means
Pharmachologic effect: Antianginal, anti-hypoxic, cytoprotective.
Testimony: Ischemic heart disease: prevention of angina attacks (in the complex therapy). Chorioretinal vascular disorders. Vertigo of vascular origin. Cochle-vestibular disorders ischemic nature (tinnitus, hearing impairment).
Contraindications: Hypersensitivity to the drug, marked disturbances of liver function, renal failure, age and 18 years of lactation, and pregnancy.
Dosing and Administration: Inside, during a meal.
The recommended dosing regime - 3.2 tablets (40-60 mg) per day in 2-3 divided doses. The course of treatment recommended by the doctor.
Release Form: 20 to 60 mg coated tablets packaged in contour.
Composition
trimetazidine dihydrochloride - 35 mg
Directly affecting cardiomyocytes and neurons in the brain, drug metabolism and optimize their function. Cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of consumption of oxygen (increased glycolysis and fatty acid oxidation blockade).
Trimetazidine maintains myocardial contractility, prevents the decrease in intracellular content of adenosine triphosphate (ATP) and phosphocreatine. The conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes intracellular concentration of potassium ions.
Reduces intracellular acidosis and elevated phosphate levels caused by myocardial ischemia and reperfusion. It prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the zone of ischemia increases the electrical potential, reduces creatine output (CK) from the cells and the severity of ischemic damage to the myocardium.
Trimetazidine reduces the frequency of angina attacks, reduces the need for taking nitrates, after 2 weeks of increases exercise tolerance, reduced the sharp fluctuations in blood pressure (BP). Reduces dizziness and tinnitus ischemic etiology. In vascular pathology eyes restores functional activity of the retina eyes.
Testimony:
Ischemic heart disease: prevention of angina attacks (in the complex therapy) .Kohleovestibulyarnye violations ischemic nature, such as vertigo, tinnitus, hearing impairment. Chorioretinal vascular disorders.
Contraindications
Hypersensitivity to any component failure preparata.Pochechnaya (CC less than 15 ml / min). Severe liver dysfunction. Age 18 years (effectiveness and safety have been established).
Dosing and Administration
Inside, during a meal. 1 tablet 2 times a day (morning and evening). The course of treatment recommended by the doctor.
Release Form
Sustained-release tablets, film-coated 35 mg.
